021-51111890
购物车（）
sales@molnova.cn
Lorlatinib
CAS No. 1454846-35-5
Lorlatinib ( PF-06463922;PF 06463922;PF06463922 )
产品货号. M11964 CAS No. 1454846-35-5
A novel CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with IC50 of 0.07/0.025 nM respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥284 | 有现货 |
|
| 5MG | ￥462 | 有现货 |
|
| 10MG | ￥705 | 有现货 |
|
| 25MG | ￥1191 | 有现货 |
|
| 50MG | ￥1920 | 有现货 |
|
| 100MG | ￥3378 | 有现货 |
|
| 500MG | ￥7679 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Lorlatinib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A novel CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with IC50 of 0.07/0.025 nM respectively.
-
产品描述A novel CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with IC50 of 0.07/0.025 nM respectively; also inhibits ALK L1196M (IC50=0.7 nM) and exhibits selectivity >100-fold for ROS1 over 204 kinases; inhibits crizotinib-resistant mutant ROS1G2032R and ROS1L2026M and orally available in vivo.Lung Cancer Phase 3 Clinical
-
同义词PF-06463922;PF 06463922;PF06463922
-
通路Angiogenesis
-
靶点ALK
-
受体ALK;ALK(L1196M);LTK(TYK1);ROS1
-
研究领域Cancer
-
适应症Lung Cancer
化学信息
-
CAS Number1454846-35-5
-
分子量406.41
-
分子式C21H19FN6O2
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 28 mg/mL
-
SMILESN#CC1=C(C(CN2C)=NN1C)C3=CN=C(N)C(O[C@H](C)C4=CC(F)=CC=C4C2=O)=C3
-
化学全称2H-4,8-Methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Zou HY, et al. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8.
2. Johnson TW, et al. J Med Chem. 2014 Jun 12;57(11):4720-44.
3. Infarinato NR, et al. Cancer Discov. 2016 Jan;6(1):96-107.
2. Johnson TW, et al. J Med Chem. 2014 Jun 12;57(11):4720-44.
3. Infarinato NR, et al. Cancer Discov. 2016 Jan;6(1):96-107.
产品手册
关联产品
-
CEP-28122 mesylate
A highly potent and selective, orally active ALK inhibitor with IC50 of 1.9 nM.
-
LDK378
Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity.
-
NVP-TAE 684
A highly potent and selective, orally available ALK inhibitor with IC50 of 3 nM in cell-free assays.
